Why Shattuck Labs (STTK) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine thesis — one sentence
Shattuck Labs shows a wide risk/reward asymmetry and large analyst-implied upside, but quality sits far below the engine's floor on extreme cash burn and the stock is technically overbought.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analysts see 110% upside, with a take-profit target of $12.90 against a current price of $7.05, though light analyst coverage dampens the signal. Sentiment breakdown | Price should close a meaningful share of the gap toward the $12.90 analyst target over the next 12 months. | ↑Improving |
| CounterLight analyst coverage explicitly dampens the reliability of the 110% upside estimate, and it may reflect just one or two analysts' views. | ||
The engine's asymmetry ratio is 5.54, one of the widest risk/reward setups screened, with 83% upside against 15% downside. Reward-to-risk math | The asymmetry ratio should stay above 3.0 as the favorable risk/reward persists. | →Stable |
| CounterThe position is flagged as speculative in a binary biotechnology industry, where a single clinical or regulatory event could erase the current asymmetry. | ||
Quality sits far below the engine's floor at 1.5 versus a 4.0 minimum, with quality notes citing extreme cash burn at -2242% of revenue and a weak Piotroski F-Score of 2/9. Bear case | FCF as a percent of revenue should improve materially over the next several quarters as cash burn narrows. | ↓Deteriorating |
| CounterInsider buying, albeit low materiality, at $37,456 suggests some insider confidence despite the weak fundamental quality score. | ||
The stock is overbought with an RSI of 78 while trading above its 200-day moving average and showing rising volume accumulation. Momentum breakdown | RSI should cool to the 50-60 range as the overbought condition resolves without a sharp price reversal. | ↑Improving |
| CounterOverbought readings in strong uptrends can persist for extended periods, so RSI alone may not be a reliable signal of an imminent pullback. | ||
Analysts see 110% upside, with a take-profit target of $12.90 against a current price of $7.05, though light analyst coverage dampens the signal.
↑Improving- Expectation
- Price should close a meaningful share of the gap toward the $12.90 analyst target over the next 12 months.
CounterLight analyst coverage explicitly dampens the reliability of the 110% upside estimate, and it may reflect just one or two analysts' views.
The engine's asymmetry ratio is 5.54, one of the widest risk/reward setups screened, with 83% upside against 15% downside.
→Stable- Expectation
- The asymmetry ratio should stay above 3.0 as the favorable risk/reward persists.
CounterThe position is flagged as speculative in a binary biotechnology industry, where a single clinical or regulatory event could erase the current asymmetry.
Quality sits far below the engine's floor at 1.5 versus a 4.0 minimum, with quality notes citing extreme cash burn at -2242% of revenue and a weak Piotroski F-Score of 2/9.
↓Deteriorating- Expectation
- FCF as a percent of revenue should improve materially over the next several quarters as cash burn narrows.
CounterInsider buying, albeit low materiality, at $37,456 suggests some insider confidence despite the weak fundamental quality score.
The stock is overbought with an RSI of 78 while trading above its 200-day moving average and showing rising volume accumulation.
↑Improving- Expectation
- RSI should cool to the 50-60 range as the overbought condition resolves without a sharp price reversal.
CounterOverbought readings in strong uptrends can persist for extended periods, so RSI alone may not be a reliable signal of an imminent pullback.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
2.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 3.6 |
| OBV | 1.0 |
| MA position | 2.2 |
| Volume | 3.4 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA but MA still rising (+2.9%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.2 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (10.0) — signal dampened
- ▸Analyst upside: 245%
Insider
7.0/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 8.9 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 3.0 |
| growth rank | 5.0 |
Technical
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 8.0 |
| support resistance | 9.3 |
| 52w position | 0.7 |
| gap | 6.0 |
Risk (lower is worse)
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.5 |
| days to cover | 1.8 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 6.5 |
| debt equity | 9.9 |
- ▸High IV: 84%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
How the verdict was assembled
Quality below minimum threshold.
Engine technical detail
L1:HARD_BLOCK:QUALITY_FLOOR- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:108d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
- MOMENTUM:2.7<4.5
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -46% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 2.7<4.5 outcome against Sentiment at 7.9 and asymmetric R:R of 0.00.
The strongest dimensions are Sentiment at 7.9, Insider at 7.0, and Technical at 6.0; the weakest are Quality at 1.6, Catalyst at 2.5, and Momentum at 2.7. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Large Analyst Upside
Trip ifAnalyst upside estimate falls below 40% from the current 110%.
- P2Wide Risk Reward Asymmetry
Trip ifAsymmetry ratio falls below 2.0, down from the current 5.54 reading.
- P3Quality Floor Extreme Cash Burn
Trip ifFCF as a percent of revenue stays below -500% for 2 consecutive quarters.
- P4Overbought Momentum
Trip ifRSI falls below 40 within 2 months, reversing the overbought condition.